New drug trial aims to ease muscle weakness in rare disease

NCT ID NCT07596784

Not yet recruiting Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called ravulizumab in 20 Chinese adults with generalized myasthenia gravis, a condition that causes severe muscle weakness. The drug is given through a vein and works by blocking a part of the immune system to reduce symptoms. Researchers will measure how well it improves daily activities and muscle strength over 26 weeks, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab (a drug given by IV infusion that blocks part of the immune system to reduce muscle weakness)
What this could lead to: If it works, this could provide a new treatment option for Chinese adults with generalized myasthenia gravis, helping them perform daily activities more easily.
What could go wrong: This is a small, early-stage trial with only 20 participants, so results may not apply to everyone. Ravulizumab can increase risk of serious infections like meningitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS GMG

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Beijing, 100053, China
Research Site

Changchun, 130021, China
Research Site

Fuzhou, 350001, China
Research Site

Jinan, 250012, China
Research Site

Shanghai, 200040, China
Research Site

Shijiazhuang, 050000, China
Research Site

Taiyuan, 030001, China
Research Site

Tianjin, 300050, China
Research Site

Wuhan, 430030, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.